TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00440843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine (Zyprexa)
Description: OLZ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typicals
Description: Stay on typicals regimen
Study: NCT00879216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA106483
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Study: NCT01170390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aviane
Description: 20 mcg EE/0.1 mg LNG continuously dosed
Study: NCT01922453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music and Sound
Study: NCT02158351

Intervention type: PROCEDURE
Intervention: liver and white adipose tissue biopsies
Study: NCT02171624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quinidine
Study: NCT03518684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalis
Description: A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping
Study: NCT00656526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine, perineural injection, intraoperatively
Description: 0.5 cc lidocaine, one single injection over the dorsal root.
Study: NCT02842450

Intervention type: DEVICE
Intervention: Photos + definitions
Description: A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.

Intervention type: OTHER
Intervention: definitions only
Study: NCT03196895

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight reduction training
Description: 6 one-hour sessions of conventional weight reduction training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PPG training
Description: Four 90-minute sessions of glycemic load and exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPG training
Description: Four 90-minute sessions of glycemic load and exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPG training
Description: Four 90-minute sessions of glycemic load and exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: discrete BG feedback
Description: Blood glucose feedback from structured self-monitoring of blood glucose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continuous BG feedback
Description: blood glucose feedback from continuous glucose monitoring
Study: NCT01580254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IOPIZE© Latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GALAXIA© Latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost RATIOPHARM© latanoprost eyedrops
Description: patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
Study: NCT02746198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic dairy drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acidified milk
Study: NCT04107298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUNDANCE™ Drug Coated Balloon
Description: Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
Study: NCT04693195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 tablets
Study: NCT02352168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal spray
Description: 64mcg/1putt, 1 putt/nostril,b.i.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 putt/nostril,b.i.d
Study: NCT03972150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study: NCT00656526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 0.5 cc %2 lidocaine,single injection
Study: NCT03666572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Bifidobacterium longum subsp. infantis (EVC001)
Study: NCT03750721

Intervention type: OTHER
Intervention: Role of rifampin in staphylococcal PJI
Description: the aim is to determine if the dose and the duration of rifampin influenced the prognosis
Study: NCT05348434

Intervention type: PROCEDURE
Intervention: 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities
Description: All patients underwent Computed Tomography (CT) scans under the condition of providing a large number of slices (more than 200 slices) per axis, and the thickness of each slice is less than 1 mm with 64-bit resolution, Then the design of the required facial implant was carried out in coordination between the designer and the surgical team. The final form of the facial implant was printed from PolyEther Ether Ketone (PEEK), and then surgical work was performed for patients under general anaesthetic according to the appropriate surgical entrance. The implants were fixed in place using titanium screws
Study: NCT03937778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep pressure block
Description: Apply deep pressure block by using blood pressure cuff.
Study: NCT00359996

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health disparities collaborative
Description: The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional educational sessions
Study: NCT03666572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Bifidobacterium longum subsp. infantis (EVC001)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Bifidobacterium longum subsp. infantis (EVC001)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
Description: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]
Study: NCT03929107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
Description: patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
Study: NCT03160339

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0047 Vaccine
Description: PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
Study: NCT03666572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
Description: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
Description: Bifidobacterium infantis with prebiotic Lacto-N-neotetraose \[LNnT\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Lactose)
Description: Placebo (Lactose)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (Lactose)
Description: Placebo (Lactose)
Study: NCT03160339

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Teva Ad4/Ad7 Vaccine
Description: Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
Study: NCT04220762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-1001X
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-1001X
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WIN-1001X
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This study has been designed as a randomized, double-blind, and placebo-controlled study.~Once the patients who have voluntarily singed an informed consent form are enrolled in this study, their eligibilities for the study are assessed and those who have satisfied the inclusion/exclusion criteria are randomized to the test group 1 (400mg), 2 (800mg), and 3 (1200mg), or the control group (placebo group) in a ratio of 1:1:1:1. The randomized patients are administered 3 tablets of the investigational product twice a day for 12 weeks and the safety follow-up should be carried out for 2 weeks after administration of the investigational product is terminated.
Study: NCT01815762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active arm
Description: In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication.
Study: NCT02271776

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Galactooligosaccharide
Description: The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study: NCT00365677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm
Description: Used with LASIK treatment for the correction of myopia and myopic astigmatism.
Study: NCT01204177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766 MEK Inhibitor + Sorafenib
Description: All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
Study: NCT02098746

Intervention type: DRUG
Intervention: Pioglitazone/glimepiride
Description: Pioglitazone/glimepiride combination tablets
Study: NCT00365677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Bausch & Lomb Zyoptix Tissue Saving algorithm
Description: Used with LASIK treatment for the correction of myopia and myopic astigmatism.
Study: NCT04689282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).
Description: Intranasal delivery of M2-BFs is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Study: NCT01773486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin
Description: Citrus polyphenol, hesperidin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching hesperidin
Study: NCT01729286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PriMatrix Moist Wound Therapy
Description: sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Moist Wound Therapy
Description: sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Moist Wound Therapy
Description: sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
Study: NCT00247403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-deoxyglucose (2DG)
Description: Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
Study: NCT01107951

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab and dexamethasone
Description: Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)
Study: NCT01230463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: 30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
Study: NCT02697370

Intervention type: DRUG
Group type: OTHER
Intervention: Pharmacokinetic based dosage change
Description: Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
Study: NCT03527238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPM-based Computation Assisted Drug Dosing
Description: Tacrolimus dosing based on application of PPM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Dosing of calcineurin inhibitor, tacrolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosing of calcineurin inhibitor, tacrolimus
Study: NCT02169167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin salve treatment
Description: Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Octenidine treatment
Description: Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
Study: NCT02174666

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red clover extract
Description: Aglycone isoflavones 80mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Supplementation (placebo)
Study: NCT03170791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vagal nerve stimulation intervention
Description: During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
Study: NCT02665338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study: NCT05299593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafluprost/timolol
Description: One ml active drug contains: 15 micrograms of tafluprost and 5 mg of timolol (as maleate).~A single-dose container (0.3 ml) of eye drops, solution, contains 4.5 micrograms of tafluprost and 1.5 mg of timolol. One drop (about 30 µl) contains about 0.45 micrograms of tafluprost and 0.15 mg of timolol. Patients will be administrered with one drop in the conjunctival sac of the affected eye (s) once a day.
Study: NCT02469857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB103 0.5 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Study: NCT01710423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention ('Cooking with Friends')
Description: 'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children.
Study: NCT03749161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-add multifocal IOL
Description: Lentis comfort, low-add multifocal, IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monofocal IOL
Description: Lentis L-313, monofocal IOL
Study: NCT03493971

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid revascularization performed using CAS
Description: Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid revascularization performed using CEA
Description: Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
Study: NCT03183206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery , IRE surgery ,surgery
Description: surgery will be used in local tumor

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: γδ T cells will be used against

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: γδ T cells/ Surgery
Description: Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
Study: NCT03409380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Arginine Drink
Description: 10 g of arginine in a formulated drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Plain Drink
Description: formulated drink
Study: NCT03418519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy
Description: Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy